




RealRate

PHARMACEUTICAL 2022

Johnson Johnson
Rank 305 of 471

Johnson & Johnson



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Johnson Johnson are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Johnson Johnson compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 95% points. The greatest weakness of Johnson Johnson is the variable Stockholders Equity, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 236%, being 40% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	51,237,000
Cost of Goods Sold	28,427,000
Intangible Assets	89,795,000
Liabilities, Current	42,493,000
Liabilities, Non-Current	44,579,000
Other Assets	15,096,000
Other Compr. Net Income	649,000
Other Expenses	2,412,000
Other Liabilities	24,544,000
Other Net Income	-2,788,000
Other Revenues	82,584,000
Property and Equipment	18,766,000
Research and Development	12,159,000
Selling, General and Administrative Expense	22,084,000

Output Variable	Value in 1000 USD
Assets	174,894,000
Liabilities	111,616,000
Expenses	65,082,000
Revenues	82,584,000
Stockholders Equity	63,278,000
Net Income	14,714,000
Comprehensive Net Income	15,038,500
BaseVar	218,806,500
ECR before Limited Liability	107%
Economic Capital Ratio	236%